United Therapeutics CEO trusts sell 9,500 shares
The exercise and resulting share sales were made under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options on October 26, 2026, at $117.7600 per share, resulting in 9,500 common shares. The resulting shares were sold through family trusts in eight reported transactions, including a 600-share sale at a weighted-average price of $585.7122 per share and an 806-share sale at $592.9168 per share. The exercise and sales were under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025; the reported option position following the exercise was 157,410.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F14, F15 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $117.76 | $1.12M |
| Sale | Common Stock F1, F3, F2 | 600 | $585.7122 | $351K |
| Sale | Common Stock F1, F4, F2 | 1,492 | $586.5445 | $875K |
| Sale | Common Stock F1, F5, F2 | 2,707 | $587.5413 | $1.59M |
| Sale | Common Stock F1, F6, F2 | 1,241 | $588.4653 | $730K |
| Sale | Common Stock F1, F7, F2 | 1,280 | $589.6378 | $755K |
| Sale | Common Stock F1, F8, F2 | 680 | $590.5669 | $402K |
| Sale | Common Stock F1, F9, F2 | 694 | $591.60 | $411K |
| Sale | Common Stock F1, F10, F2 | 806 | $592.9168 | $478K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F11 | -- | -- | -- |
| holding | Common Stock F12 | -- | -- | -- |
| holding | Common Stock F13 | -- | -- | -- |
Footnotes (15)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $592.46 to $593.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F14. These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
- F15. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $585.01 to $585.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $586.035 to $587.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $587.04 to $588.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $588.09 to $589.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $589.10 to $590.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $590.20 to $591.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $591.36 to $592.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
pre-arranged 10b5-1 trading plan financial
weighted average price financial
stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What option exercise did UTHR Chairperson & CEO Martine A. Rothblatt report?
When does the UTHR Rule 10b5-1 trading plan end?
AI-generated analysis. How Rhea-AI works. Not financial advice.